Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Thaw In Sight: German Bill Extends Price Freeze To 2022

Executive Summary

Drug price freeze introduced in 2010 would remain to 2022, under draft legislation to revise AMNOG reimbursement system. It introduces some limits on the year of free pricing that companies enjoy after launch.

You may also be interested in...



Germany May Make Drug Prices Confidential In AMNOG Update

Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.

Germany Cuts Pharma Rebate Level While Keeping Price Freeze

German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.

Is International Reference Pricing Still Relevant?

International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.

Topics

Related Companies

UsernamePublicRestriction

Register

PS118861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel